Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors in the central nervous process, conolidine modulates alternate molecular targets. A Science Innovations research observed that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://busterg218wxx8.wikiworldstock.com/user